SEC Form 4 · accession 0000950138-17-000454
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Coleman N Lannum III
Officer — Sr. VP Investor Strategy & IRO
Period of report
Jun 2, 2017
Accepted (ET)
Jun 5, 2017 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jun 2, 2017 | P | 1,350 | $42.892 | A | 30,955 | D | |
| Ordinary Shares | holding | — | — | — | 1,600 | I | By Wife | |
| Ordinary Shares | holding | — | — | — | 75 | I | By son (M) | |
| Ordinary Shares | holding | — | — | — | 45 | I | By son (R) | |
| Ordinary Shares | holding | — | — | — | 45 | I | By son (S) | |
| Ordinary Shares | holding | — | — | — | 20 | I | By mother |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $42.68 to $43.22, inclusive. Mr. Lannum will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range.